Characterization of the Early Ultrastructural and Biochemical Events Occurring in Dichloromethane Diphosphonate Nephrotoxicity

Abstract

A chelator, dichloromethane diphosphonate (Cl2MDP), used to treat for malignancy-induced hypercalcemia, has nephrotoxic potential. An acute animal model developed to examine the mechanism was used to further characterize the renal effects. NAG enzymuria appears to be an early premonitor of injury. Ultrastructurally, an increase in size and number of protein-containing phagolysosomal reabsorption droplets in proximal convoluted tubules associated with proteinuria precedes advent of tubular cell necrosis indicating these organelles to be a potential target site for Cl2MDP in the kidney. In vitro studies using rabbit cortical tubules and rat brush border membrane vesicle preparations suggest that the renal toxicity is not due to perturbation of phosphate transport or oxidative metabolism. An operational hypothesis emerges indicating that Cl2MDP may be protein bound affecting carrier protein charge facilitating glomeruler leakage with tubular accumulation via protein transport. Cl2MDP may induce critical cation perturbation at the subcellular level as the mechanism of cell death.

Keywords

Nephrotoxicity Cl2MDP chelator in vitro

References

Alden CL

Burns J

, and

Parker R

(1987). Bisphosphonate nephrotoxicity: Model development and proposed mechanism of injury. Presented at 1987 American College of Veterinary Pathologists Meeting, Monterey, CA.

Alden CL

Parker R

, and

Eastman DF

(1989). Development of an acute model for the study of chloro-methane diphosphonate nephrotoxicity. Toxicol. Pathol.17:27–32.

Brazy PC

Gullans SR

Mandel L

, and

Dennis V

(1982). Metabolic requirement for inorganic phosphate by the rabbit proximal tubule. J. Clin. Invest.70:53–62.

Cheng L

and

Sacktor B

(1981). Sodium gradient-dependent phosphate transport in renal brush border membrane vesicles. J. Biol. Chem.256(4): 1556–1564.

Chung TY

Price RG

Chattagoon L

Richardson AC

, and

Praill PFG

(1982). Colorimetric assays for N-ace-tyl-B-D-glucosaminidase and B-D-galactosidase in human urine using newly developed w-nitrostyryl sub strates. Clin. Chim. Acta124: 195–204.

Douglas DL

Duckworth T

Russell RGG

Kanis JA

Preston CJ

Preston FE

Prenton MA

, and

Woodhead JS

(1980). Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcemia due to primary hyperparathyroidism of malignant disease. Lancet1:1043–1047.

Jacobs TP

Siris ES

Bilezikian JP

Bequiran DC

Shane E

, and

Canfield RE

(1981). Hypercalcemia of malignancy. Treatment with intravenous dichloromethylene diphosphonate. Ann. Intern. Med.94:213–216.

Jung A

(1982). Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am. J. Med.72:221–226.

Van Breukelen FJM

Bijvoet OLM

, and

Van Oosterom AT

(1979). Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (ADP). Lancet1:803–805.